A Multicenter, Prospective, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared with Placebo in Type 2 Diabetes Mellitus Patients Having Hypertriglyceridemia Not Controlled with Atorvastatin Therapy (PRESS VI)

Pharmacokinetics, Safety, and Tolerability of Saroglitazar (ZYH1), a Predominantly PPARα Agonist with Moderate PPARγ Agonist Activity in Healthy Human Subjects

(2013) Rajendra H. Jani et al.   CLINICAL DRUG INVESTIGATION

Standards of Medical Care in Diabetes--2013

(2012)   DIABETES CARE

Effects of Fibrates in Kidney Disease

(2012) Min Jun et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030

(2011) David R. Whiting et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Risk factor levels, risk factor combinations, and residual coronary risk: population-based estimates for secondary prevention patients using statins

(2011) Karl J Krobot et al.   European Journal of Preventive Cardiology

Management of Diabetes Mellitus in Patients With Cardiovascular Disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial

(2010) Allison B. Goldfine et al.   CIRCULATION

Targets of Statin Therapy: LDL Cholesterol, Non-HDL Cholesterol, and Apolipoprotein B in Type 2 Diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS)

(2009) V. Charlton-Menys et al.   CLINICAL CHEMISTRY

Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study

(2009) Robert R Henry et al.   LANCET